Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome
Status:
Recruiting
Trial end date:
2022-06-28
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center study of carisbamate in adult and pediatric subjects with
LGS, with single- and multiple-dose PK assessments from Days 1 through 73. There will be a
Screening Period of up to 28 days and a Treatment Period of 87 days.